Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

BACKGROUND: Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–targeting antibodies have been evaluated, largely in patients with t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Rajan, Arun, Heery, Christopher R., Thomas, Anish, Mammen, Andrew L., Perry, Susan, O’Sullivan Coyne, Geraldine, Guha, Udayan, Berman, Arlene, Szabo, Eva, Madan, Ravi A., Ballester, Leomar Y., Pittaluga, Stefania, Donahue, Renee N., Tsai, Yo-Ting, Lepone, Lauren M., Chin, Kevin, Ginty, Fiona, Sood, Anup, Hewitt, Stephen M., Schlom, Jeffrey, Hassan, Raffit, Gulley, James L.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805423/
https://ncbi.nlm.nih.gov/pubmed/31639039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0723-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars